Abstract: Provided is a novel analysis method that enables identification of a sample even when any sample is introduced during measurement carried out by using a chemical sensor. An input in which the amount of an unknown sample changes over time is provided to the chemical sensor, a response which is from the chemical sensor and which changes over time is measured, a sensor function (transmission function) of the chemical sensor with respect to the unknown sample is calculated on the basis of the input and the response, and the unknown sample is identified on the basis of the sensor function of the chemical sensor with respect to the unknown sample.

Abstract: Gas analyzer and method for measuring nitrogen oxides in an exhaust gas, wherein to measure the nitrogen oxides, ozone is generated from oxygen, the exhaust gas is treated with the ozone generated to convert nitrogen monoxide within the exhaust gas into nitrogen dioxide, the nitrogen dioxide concentration in the treated exhaust gas is measured photometrically using a first light-emitting diode which emits with a central wavelength between 350 nm and 500 nm and output as the nitrogen oxide concentration in the exhaust gas, and the ozone concentration in the treated exhaust gas is measured photometrically using a second light-emitting diode which emits with a central wavelength between 250 nm and 265 nm, where generation of the ozone using the measured ozone concentration as an actual value is regulated to a prespecified setpoint value to enable reliable continuous measurement of nitrogen oxides in exhaust gases with a low outlay on equipment.

Abstract: A device for the detection of conditions indicative of illicit drug production. The device includes an airborne ethanol sensor circuit configured to output a signal indicative of airborne ethanol concentration. A processor is coupled to the airborne ethanol sensor circuit, configured to receive the signal indicative of airborne ethanol concentration. The processor is configured to determine whether a value of the signal exceeds a predetermined threshold. A communication circuit is coupled to the processor, configured to send a message to at least one remote address on determination of the value of the signal exceeding the predetermined threshold.

Abstract: A method for the inactivation and inactivation testing of xenoantigens in foods of vegetable and animal origin, comprising the following steps: making up a solution with a food of vegetable or animal origin as a solvent and one or more phenolic compounds, polyphenolic compounds and derivatives thereof, comprising phenylpropanoids, as a solute, for the inactivation of at least part of the xenogeneic epitopes from said food, incubating samples of the food of vegetable or animal origin with the addition of an antibody aimed at a xenoantigen epitope that is present in the food, separating the resulting immune complex created owing to the bond between antigen and antibody, preparing a well plate for the E.L.I.S.A.

Abstract: A rock sample includes multiple rock samples that are each obtained from the borehole. The rock samples have been exposed to contamination during a drilling operation to drill the borehole. The rock sample is split into a first sample portion and a second sample portion. The first sample portion is decontaminated with a solvent. The second sample portion is decontaminated by thermovaporization for an initial duration of time at an initial thermovaporization temperature below that of a cracking temperature of an organic matter carried within the rock sample. A difference between a first pyrolysis Tmax value of the first sample portion decontaminated by the solvent and a second pyrolysis Tmax value of the second sample portion decontaminated by the thermovaporization is determined to satisfy a decontamination level threshold. The remainder of rock samples are decontaminated by the thermovaporization in response to determining that the difference satisfies the decontamination level threshold.

Abstract: A measurement cell includes: an enclosure; a flexible membrane disposed in the enclosure so as to contain a hardenable material; and means for stiffening the membrane configured to assume two alternative states: a stiffness state, in which the stiffening means resist the expansion of the hardenable material during solidification; and a flexible state, in which the stiffening means exert a stress that is less than that exerted in the stiffness state allowing at least one physical, chemical or mechanical property of the hardenable material to be measured and the hardenable material to be extracted from the enclosure; the stiffening means being produced by a set of metal wires connected to a clasp configured to modify the stiffness exerted by the metal wires.

Abstract: Embodiments of the disclosure are directed to a device for molecule sensing. In some embodiments, the device includes a first electrode separated from a second electrode by a dielectric layer. The first electrode comprises a large area electrode and the second electrode comprises a small area electrode. At least one opening (e.g., trench) cut or otherwise created into the dielectric layer exposes a tunnel junction therebetween whereby target molecules in solution can bind across the tunnel junction.

Abstract: The invention relates to a device and a method for cancer detection and screening, based on analysis of Volatile Organic Compounds emitted by certain cancerous tumors. The device and method provide high sensitivity and specificity analyses. The sample to be analysed may be e.g. blood or blood plasma. In one aspect, the invention is directed towards detection of or screening for gynaecological cancers, e.g. ovarian cancer. Particularly, the device comprises the following parts: a sample holder for a fluid or solid body sample; an air inlet; a detector tube comprising 4×4-16×4 sensors; optionally an individual potentiometer connected to each sensor of the detector tube; an analogue to digital signal converter; four control cards; a computer-based program for the registration and statistical calculation of results; and an electricity source.

Abstract: Disclosed herein are methods and devices for measurement of carbon dioxide and nitric oxide in exhaled breath of patients at risk for or suffering from sepsis. Carbon dioxide and nitric oxide levels may be measured in controlled rate breath and/or end tidal breath, and a risk score for the patient developing or having sepsis may be determined. In many embodiments, carbon dioxide and nitric oxide measurements are determined simultaneously in a single breath, and by a single measurement apparatus, while other embodiments measure nitric oxide and carbon dioxide levels using separate measure apparatuses and/or in different breaths of the patient.

Abstract: The use of genomic tests shows variability between the primary tumor and the metastases in most circumstances referred to as tumor heterogeneity. Since it is unduly invasive and difficult to obtain samples from the primary and metastatic tumors within a patient, a need exists for a method of testing chemotherapeutic effectiveness in a patient that is applicable to both primary tumor and metastases. Provided are methods of using the MiCK assay to determine the most effective drug candidate(s) for an individual patient by testing a single tumor site. In a further embodiment, the kinetic unit (KU) value obtained by analysis of cancer cells from a tumor site in an individual patient in the presence of a drug candidate is within two standard deviations of the KU value obtained by analysis of a different tumor site in the patient in the presence of the same drug candidate.

Abstract: The present invention provides method for monitoring physiological status of an organ in a subject by monitoring morphological changes over time in transplanted tissue on an eye of the subject.

Abstract: The increased efficacy and reduced unwanted side effects of drugs can be insured by treating only responsive patients. In an embodiment of the invention, signaling pathways that a particular drug interferes with, are derive together with predictive biomarkers and dynamic biomarker that can read the activity of these pathways before and after drug treatment in order to select a responder patient population. In an alternative embodiment of the invention, certain core pathways that the drug does not interfere with and that are known to be causally involved in a particular disease(s) can be identified, and derive the biomarkers for those to be able to exclude these patients that suffer from a disease in which those drug non effected pathways are involved from being treated with the specific drug in question.

Abstract: Methods of imaging described herein comprises disposing a first and second ultrasound-switchable fluorophore in an environment; exposing the environment to an ultrasound beam to create an activation region; disposing the first and/or second fluorophore within the activation region to switch the first and/or second fluorophore from an off state to an on state; exposing the environment to a beam of electromagnetic radiation; detecting a first photoluminescence signal at a first location within the environment, the photoluminescence signal comprising at least one of a first ultrasound fluorescence signal emitted by the first fluorophore, a first fluorescence signal emitted by the second fluorophore, and a background signal; correlating the first photoluminescence signal with a first reference signal to generate a correlation coefficient for the first location; and multiplying the first photoluminescence signal by the first correlation coefficient for the first location to generate a first modified photoluminesce

Abstract: A system and method for identifying an analyte based on the presence of at least one volatile organic compound (“VOC”) in the analyte. The method includes: receiving image data from a sensor array, the sensor array having been exposed to the analyte, the sensor array including at least one sensor configured to respond to the presence of the at least one VOC in the analyte; processing the image data to derive one or more input image features; and using a trained machine learning classification technique, detecting the at least one VOC and classifying the analyte based on the one or more input image features, the machine learning classification technique trained using one or more reference images of known analytes.

Abstract: Kits, compositions, and methods for labeling target materials or target analytes are considered. The composition can include one or more affinity molecules indirectly conjugated to one or more detection moieties. The kit can be used to detect a single biomarker or multiple biomarkers. The kit can be used to perform a single round of labeling or multiple rounds of labeling.

Abstract: A processing and detection system for detecting presence of at least one gluten protein in a food sample comprises a food processor including: a reservoir containing a process liquid for processing the food sample; a body that comprises a chamber configured to receive the food sample; and a pressing surface configured to press on the reservoir to cause the process liquid to exit the reservoir and mix with the food sample, thereby generating a processed food liquid; and an exit port configured to conduct the processed food liquid out of the food processor; and a cartridge including: at least one sensor configured to receive the processed food liquid and to generate an electrical signal in response to interaction with the at least one gluten protein in the processed food liquid, and an analyzer in electrical communication with the at least one sensor for detecting the electrical signal and determining the presence of the at least one gluten protein in the food sample based on the detected electrical signal.

Abstract: Analyzing samples injected into an inductively coupled plasma source can be improved by one or more of a stabilizing solution mixable with a sample prior to injection and a heated injector. The stabilizing solution can minimize the difference in osmotic pressure between the solution and the cells with a relatively low amount of dissolved solids (e.g., at or below about 0.2%). The stabilizing solution can contain a salt (e.g., ammonium nitrate) present in concentrations of at least 5 mM. The injector can be heated before and/or during injection. In some cases, heat from adjacent parts can be channeled into the injector to improve heating of the injector. An injector heated to sufficient temperatures can minimize solute buildup and can extend the usable time between cleanings. These improvements can be especially useful in elemental analysis, such as inductively coupled plasma mass spectrometry or inductively coupled plasma optical emission spectrometry.

Abstract: Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.

Abstract: Methods of making an integrated circuit for a single-molecule nucleic-acid assay platform. In one example, the method includes adhering a carbon nanotube to a surface of a transfer film, the transfer film comprising gold or a polymer; placing the surface of the transfer film on a CMOS integrated circuit; releasing the carbon nanotube from the transfer film; and forming a pair of post-processed electrodes proximate opposing ends of the carbon nanotube, the post-processed electrodes electrically connecting the carbon nanotube to the CMOS integrated circuit. The method can also include exposing the carbon nanotube to a diazonium salt solution to form a point defect on a portion of the carbon nanotube.

Abstract: The invention describes a method for the identification of compounds which bind to a target component of a biochemical system or modulate the activity of the target, comprising the steps of: a) compartmentalising the compounds into microcapsules together with the target, such that only a subset of the repertoire is represented in multiple copies in any one microcapsule; and b) identifying the compound which binds to or modulates the activity of the target; wherein at least one step is performed under microfluidic control. The invention enables the screening of large repertoires of molecules which can serve as leads for drug development.

Abstract: Herein is reported a method for determining the binding of an antibody, which comprises a first binding site specifically binding to a first antigen and a second binding site specifically binding to a second antigen, to said first and said second antigen, wherein the method comprises the steps of capturing the antibody on a solid phase using a capture reagent specifically binding to a constant domain of the antibody, incubating the captured antibody with the first or the second antigen to form a captured antibody-antigen complex and determining a first binding signal, either i) incubating the captured antibody-antigen complex with the antigen not used for the formation of the captured antibody-antigen complex to form a captured antibody-antigen-antigen complex and determining a second binding signal, or ii) regenerating the surface, capturing the antibody on a solid phase using a capture reagent specifically binding to a constant domain of the antibody, incubating the captured antibody with the antigen not us

Abstract: A method is described for the detection of at least two of cytokeratins 8, 18 and 19 in a sample. It is practiced by contacting the sample with a solid phase having a first antibody with specificity for cytokeratin 8, a second antibody with specificity for cytokeratin 18 and, optionally, a third antibody with specificity for a first epitope of cytokeratin 19 bound to it and allowing cytokeratins in the sample to bind to the bound antibodies to form complexes. The complexes are then contacted with a first labelled antibody with specificity for a dimer of cytokeratin 8 and 18 and optionally a second labelled antibody with specificity for a second epitope of cytokeratin 19 and allowing the labelled antibodies to bind to the complexes. The labelled antibodies bound to the complexes are then detected. A method for quantitative determination of soluble fragments of at least two of cytokeratin 8, 18 and 19 in a sample and a kit are also described.

Abstract: In one embodiment, the present invention includes a system for detecting a target analyte which includes a microfluidic device having least one microfluidic channel with a binding surface positioned in the microfluidic channel with further include a first electrode and a second electrode. The system may further include a detector and a voltage supply. Also included is a method to detect a target analyte using a described microfluidics device, introducing solution with a target analyte to a binding surface, and binding the target analyte to the binding surface by applying an electrical potential between the first and second electrodes during at least a portion of the binding step, which enhances the rate of binding of the target analyte molecules to the binding molecules. The method then includes the steps of detecting a reporter molecule which corresponds to the amount of the bound target analyte molecules, which correlates with the amount of target analyte in the original sample.

Abstract: The invention relates to ex-situ biosensors that impedimetrically detect one or more target biomarkers of interest in bodily fluid sample derived from a patient. The biosensors include a multi-array of conducting material, such as platinum wires, having immobilized thereon antibody and/or aptamer that is selected to specifically and selectively bind to the one or more target biomarkers of interest. The biosensors are contacted with a portion of the bodily fluid sample, and the antibody and/or aptamer binds to the target biomarker(s) of interest in the bodily fluid sample. As a result, an electrochemical impedance signal is generated and therefore, a change in the electrochemical impedance is indicative of the presence of the target biomarker(s) of interest in the bodily fluid sample. The biosensors are point-of-care, on-demand devices that can be used in a medical environment, as well as in domestic and health emergency settings.

Abstract: Disclosed herein are methods for forecasting response to lupus nephritis (LN) therapy in individual diagnosed with childhood-onset SLE (cSLE). The methods may include the step of detecting each protein in a protein set in a sample obtained from an individual in need thereof. The protein set may include ceruloplasmin, kidney injury molecule 1 (KIM-1), monocyte chemotactic protein 1 (MCP-1), adiponectin, hemopexin, and NGAL.

Abstract: An in-vitro method for early diagnosing or prediction of immune-mediated inflammatory diseases, comprising: —obtaining a sample from a subject; —quantifying simultaneously by one LC/MS-MS analysis of said sample, a presence of V65 vitronectin fragment or fragment, variant or degradation product thereof; and a presence of a complement C3f or fragment or variant or degradation products thereof;

Abstract: Means and methods for determining whether an individual that does not have rheumatoid arthritis, AAV or Sjögren syndrome at the moment of sampling is at risk of developing the disease, the method comprising determining whether an antibody-containing sample of the individual comprises an autoantibody associated with the disease that comprises an N-linked glycosylation at one or more positions in a Fab-portion of the antibody, the method further comprising determining the risk of the individual for developing the disease. The disease is preferably rheumatoid arthritis.

Abstract: The object is to provide a lysis method, lysis treatment solution, detection method using an immunochromatographic device, and detection kit comprising an immunochromatographic device for detecting whether causative bacteria of mastitis are coliform bacteria or not by using milk of a livestock animal. There is provided a method for lysing coliform bacteria, which comprises the step of mixing a lysis agent containing a lytic enzyme, and at least one kind of anionic surfactant, and preferably further containing at least one kind of nonionic surfactant, with milk obtained form a livestock animal to lyse coliform bacteria existing in the milk. The lytic enzyme is preferably lysozyme.

Abstract: Provided herein are Zika virus (ZIKV) binding constructs, e.g., antibodies and antigen-binding fragments thereof and antibody mimetics, as well as related conjugates, polypeptides, nucleic acids, expression vectors, host cells, kits, and assay systems. Methods detecting ZIKV infection and/or ZIKV exposure and/or ZIKV immunity are provided.

Abstract: Methods and compositions for detecting BoNT/A enzymatic activity in tissues or a tissue sample are described herein. The invention encompasses antibodies that bind preferentially to BoNT/A cleaved SNAP25 and is able to preferentially detect BoNT/A cleaved SNAP25, as compared to intact (non-cleaved) SNAP25, in a tissue sample.

Abstract: A method for examining liver cancer or a method for assisting diagnosis of liver cancer that is superior in sensitivity and specificity, as well as a kit that can be used therefor is provided. The present invention provides a method for detecting liver cancer or a method for assisting diagnosis of liver cancer comprising a step of detecting or quantifying free AIM in a biological sample derived from a test subject, as well as a kit for examining or assisting diagnosis of liver cancer comprising an antibody that binds to free AIM.

Abstract: This invention relates to novel approaches for the identification and stratification of subtypes of pancreatic ductal adenocarcinoma (PDAC), in particular to novel PDAC subtype-specific markers, and to diagnostic kits comprising reagents for detecting said markers.

Abstract: The present invention relates to a composition for diagnosis of pancreatic diseases, more specifically, to a composition which can diagnose pancreatic cancer, a kit for diagnosis comprising the same, and a method of providing information for diagnosis using the composition. The present invention can accurately predict or identify the risk of pancreatic cancer, and moreover, can diagnose pancreatic cancer by effectively distinguishing pancreatic cancer from different types of cancer. In addition, in the present invention, it is possible to diagnose pancreatic cancer simply and rapidly through a non-invasive method by using monocytes obtained from blood, serum or plasma obtained from an individual.

Abstract: Methods and compositions are provided for specific aptamers and aptamer pools that bind biomarkers of interest such as microvesicle surface antigens or functional fragments of microvesicle surface antigens. In various embodiments, aptamers of the invention are used in diagnostic, prognostic, or theranostic processes to screen a biological sample for the presence or levels of biomarkers such as microvesicles that are determined to provide a diagnostic, prognostic, or theranostic readout. The diagnosis, prognosis, or theranosis may be related to cancer or other diseases and disorders. The invention also provides methods and composition to facilitate aptamer library screening and aptamer detection methods.

Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of cancer, such as lymphoma, myeloma, leukemia, thyroid cancer, bladder cancer, breast cancer, gastric cancer, esophagus cancer, head and neck cancer and skin cancer, for monitoring the effectiveness of cancer, such as lymphoma, myeloma, leukemia, thyroid cancer, bladder cancer, breast cancer, gastric cancer, esophagus cancer, head and neck cancer and skin cancer treatment, and for drug development.

Abstract: Glycans having a branched structure are labeled with a labeling agent, such as 2-aminobenzoic acid, having one site that is easily negatively charged. At this time, reduction which is usually performed in labeling by reduction amination is not performed. A sample for mass spectrometry containing the labeled form of glycans thus obtained is prepared, and is subjected to MS/MS analysis in negative ion mode. In the MS/MS spectra obtained by the MS/MS analysis, peaks of E ions, D ions and the like which reflect the branched structure clearly appear. As a result, structural analysis of an entirety of the glycan including the branched structure can be easily performed.

Abstract: In one aspect, the present invention is generally directed to methods for measuring distribution of lengths of a collection of carbon nanotubes. In particular, the present teachings provide an indicator for length-based separation of carbon nanotubes (CNTs) via conjugation of one or more biomolecules onto the surfaces of the nanotubes. As discussed in more detail below, in some embodiments, such a method can include conjugating a biomolecule to the carbon nanotubes and subject the conjugated carbon nanotubes to silver-stained gel electrophoresis to separate the conjugated carbon nanotubes based on their lengths.

Abstract: Disclosed is a method of pulsed laser ablation production of gold-platinum AuxPt1-x alloy nanoparticles in a colloidal solution. The colloidal solution of AuxPt1-x alloy nanoparticles is suitable for many biological applications including lateral flow immunoassays and other bio-detections based on optical scattering. The nanoparticles form by fragmentation of the bulk material without evaporation, minimizing oxidation of the nanoparticles. The nanoparticles conjugate with bio-molecules such as protein, antibodies, peptides, RNA oligomers, DNA oligomers, other oligomers, or polymers effectively by passive adsorption. Advantageously the AuxPt1-x alloy nanoparticles have a wide optical extinction spectrum in the visible region, appearing nearly black in both colloidal and dried form. The nanoparticles can be used for labeling bio-molecules and provide a high visual contrast in visual-based bioassays.

Abstract: An optical analyte sensor and diabetes management system is provided. The sensor preferably includes a hydrogel matrix for receiving a sample containing an analyte at unknown concentration, a light emitter for emitting light at a stimulation frequency, a light receiver for receiving a fluorescence signal at a first isosbestic frequency, and at a second frequency, for measuring an intensity of the fluorescence signal and the first and second frequencies. A processor determines a concentration of the analyte based on the respective intensities.

Abstract: A method for screening compounds for their ability to interact with transmembrane proteins is provided. Also provided is a method for determining whether proteins such as transmembrane proteins are able to oligomerise.

Abstract: The purpose of the present invention is to provide: a method for predicting the prognosis for kidney disease for a subject on the basis of the amount of D- and L-amino acids, from a blood sample; and an analysis system that determines prognosis predictions. This purpose is achieved by using at least one amino acid to predict the prognosis for kidney disease, said amino acid being selected from the group consisting of D-serine, D-asparagine, D-proline, D-alanine, D-leucine, D-lysine, D-allo-isoleucine, L-glutamic acid, L-alanine, L-tryptophan, and L-asparagine.

Abstract: The disclosure provides biomarker panels, methods and kits for determining the probability for preterm birth in a pregnant female. The present disclosure is based, in part, on the discovery that certain proteins and peptides in biological samples obtained from a pregnant female are differentially expressed in pregnant females that have an increased risk of developing in the future or presently suffering from preterm birth relative to matched controls. The present disclosure is further based, in part, on the unexepected discovery that panels combining one or more of these proteins and peptides can be utilized in methods of determining the probability for preterm birth in a pregnant female with relatively high sensitivity and specificity. These proteins and peptides disclosed herein serve as biomarkers for classifying test samples, predicting a probability of preterm birth, monitoring of progress of preterm birth in a pregnant female, either individually or in a panel of biomarkers.

Abstract: The application discloses new biomarkers for early-onset preeclampsia based on the finding that the ratio between GBP-1 and ESM-1 in plasma samples was significantly increased in women that develop severe early-onset pre-eclampsia compared to healthy control pregnancies: the ratio between GBP-1 and ESM-1 is a prognostic parameter to identify the women at risk for severe early-onset pre-eclampsia as early as 12±2 weeks of gestation and can serve both as an important rule-in and rule-out parameter.

Abstract: Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.

Abstract: Provided herein are methods and devices for the detection of conditions or disorders by detecting altered levels of stress response pathway biomarkers. Also provided are methods and reagents for identifying panels of biomarkers associated with a condition or disorder.

Abstract: A method for identifying inhibitors of the primary nucleation of amyloid beta aggregation includes providing an A-beta species in solution or in a buffer, and determining the amyloid-beta aggregation, wherein the A-beta species comprises two A-beta monomer units with a linker arranged between the A-beta monomer units is provided. A method for analyzing aggregation of monomers of protein misfolding diseases and a kit are also provided.

Abstract: An object of the present invention is to provide a blood analysis method and a blood test kit, which are capable of performing measurement of a plurality of target components to be analyzed with high accuracies in a case where hemolysis occurs in a case of measuring an amount of target components to be analyzed in a small volume of a blood sample.

Abstract: A method for measuring bilirubin levels in a subject. The method can include the steps of providing a sample to be measured from the subject, wherein the sample comprises bilirubin bound to albumin; adding a release agent to the sample, the release agent configured to release the bound bilirubin from the albumin; measuring electrochemical data of the sample using an electrochemical cell; and determining a total serum bilirubin concentration of the sample using the electrochemical data. This method is capable of providing a simpler, faster, and more robust measurement when compared to traditional bilirubin assay methods.

Abstract: A method for assessing susceptibility to nausea of a patient comprises assessing the GSH recycling dependent antioxidant activity of the patient's blood cells prior to receiving an emetogenic agent, e.g., a cytostatic agent or a surgical anesthetic.

Abstract: A method and system for user-friendly point of care assay is described. The cartridge utilizes a lateral flow assay, buffer chambers and capillary sample collection. The sample is first collected by the capillary tube attached to the cartridge. The cartridge is then actuated, drawing the sample into the lateral flow strip and introducing a buffer liquid into the system thereby automatically performing the assay. An electronic reader may be used to measure the results of the assay.